Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cogent BiosciencesCOGT +2.74%30 Earnings Yield (Joel Greenblatt) % is -5.82% as of Mar. 2026. GuruFocus rates COGT with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 1,322 Biotechnology companies, Cogent Biosciences ranks better than 59.83% on this metric.
Cogent Biosciences's Enterprise Value for the quarter that ended in Mar. 2026 was $6,010.12 Mil.
Cogent Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-350.03 Mil. Cogent Biosciences's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was -5.82%.
The historical rank and industry rank for Cogent Biosciences's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
COGT'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11191.24 Med: -20.24 Max: 7289.63
Current: -5.46
During the past 11 years, the highest Earnings Yield (Joel Greenblatt) of Cogent Biosciences was 7289.63%. The lowest was -11191.24%. And the median was -20.24%.
COGT's Earnings Yield (Joel Greenblatt) % is ranked better than 59.83% of 1322
companies
in the Biotechnology industry
Industry Median: -10.15
vs COGT: -5.46
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Cogent Biosciences's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Cogent Biosciences Earnings Yield (Joel Greenblatt) % Related Terms
Cogent Biosciences Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Cogent Biosciences's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cogent Biosciences's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cogent Biosciences Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cogent Biosciences's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Cogent Biosciences's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Cogent Biosciencess Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Cogent Biosciences's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-350.03 Mil.
What does a Earnings Yield (Joel Greenblatt) % of -5.82% mean?
Cogent Biosciences (COGT) has a Earnings Yield (Joel Greenblatt) % of -5.82% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cogent Biosciences and its competitors. According to the industry distribution chart, Cogent Biosciences ranks #531 out of 1322 companies in the Biotechnology industry, placing it in the top 40.2%.
Is Cogent Biosciences' Earnings Yield (Joel Greenblatt) % too high?
Cogent Biosciences' current Earnings Yield (Joel Greenblatt) % is -5.82%. Based on the distribution chart, Cogent Biosciences ranks #531 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Cogent Biosciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Cogent Biosciences' Earnings Yield (Joel Greenblatt) % compare to MIRM and ERAS?
According to the Biotechnology industry distribution chart, Cogent Biosciences ranks #531 out of 1322 companies for Earnings Yield (Joel Greenblatt) %. This puts Cogent Biosciences in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Cogent Biosciences and its competitors. Cogent Biosciences's current Earnings Yield (Joel Greenblatt) % is -5.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cogent Biosciences stock overvalued right now?
Cogent Biosciences (COGT) has a current Earnings Yield (Joel Greenblatt) % of -5.82%. The current Earnings Yield (Joel Greenblatt) % is -5.82%. Cogent Biosciences' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Cogent Biosciences (COGT), the current Earnings Yield (Joel Greenblatt) % is -5.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
30GF Score
Get the complete analysis for COGT
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COGT has been successfully added to your 
